Table of Contents

Abstracts / 21st Annual Congress, Amsterdam, The Netherlands 24–28 September 2011

01 September 2011; volume 38, issue Suppl 55

41. The COPD patient experience: care and management

42. New insights in the treatment of idiopathic pulmonary fibrosis

43. Early diagnosis in primary care

44. Smoking cessation science

45. Mechanisms and outcomes of infective exacerbations of COPD

46. Skeletal muscle weakness in COPD: physical (in)activity and biological markers

47. Macrophages and neutrophils in chronic lung disease

48. Immunobiology in the transplanted lung: experimental and clinical evaluations

49. Are needles really enough?

50. COPD management

51. Allergen immunotherapy and anti-immunoglobulin E

52. Physical activity, methodology and impact

53. Tuberculin skin tests, interferon-gamma release assays and beyond

54. Genetic and environmental risk factors for respiratory diseases

63. Mechanism and monitoring of airway diseases

64. Cystic fibrosis: new aspects of diagnosis, inflammation and detecting exacerbation

65. Endoscopic lung volume reduction: hype or hope?

66. Altered mechanisms during exercise in disease

67. Treatment of lung cancer

68. Multidrug-resistant tuberculosis

69. Diagnosis and predictors of COPD exacerbation

70. Treatments for pulmonary hypertension in human and experimental models

71. Recent developments in COPD

72. Genetics of airway diseases and treatment

73. Pleural diseases and pneumothorax

74. Biomarkers of allergic inflammation

75. The new clinical spectrum of lung diseases: from bronchi to pleura

76. Innate and exogenous factors in childhood respiratory infection

78. Asthma: a heterogeneous disease

79. COPD management

80. COPD exacerbation

81. Vascular and parenchymal imaging

82. From outside to inside: access to the pleura

83. To stent or not to stent: interventional bronchoscopy

84. Rare diffuse lung diseases

85. What is new in the approach to pulmonary fibrosis?

86. Experimental models and research in diffuse parenchymal lung diseases

87. Quality of life and respiratory symptom management in primary care

88. New mechanisms in airway disease

89. COPD: human studies

90. Airway smooth muscle cells and fibroblasts: cell biology

91. Lung cell biology

92. The ageing pulmonary interstitium

93. Anti-inflammatory strategies in acute lung injury

94. Drug delivery and pharmacokinetics I

95. Translational models of disease

96. Bronchodilators in asthma and COPD

97. Asthma: control and treatment

98. Monitoring exacerbations of airway diseases

99. Monitoring with lung function tests in airway diseases

100. Clinical parameters in airway diseases

101. Animal models of airway inflammation

102. Asthma: risk factors and comorbidities

103. Respiratory epidemiology: genetics and modifiable risk factors

104. Respiratory epidemiology: comorbidity

105. Air pollution

106. Mineral dusts

107. Smoking cessation science and smoking-related disorders

108. Smoking rate: smoking cessation interventions

109. New insights in paediatric respiratory physiology

110. Risk and detection of childhood asthma and allergy

111. Paediatric respiratory infection: signs, symptoms and sequelae

112. Paediatric epidemiology: bronchiolitis, pneumonia, asthma and spirometry in non-respiratory conditions

113. Lung function today and tomorrow I

114. Lung function today and tomorrow II

115. Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation

116. Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care

117. Rehabilitation, outcome measures and effects

118. Respiratory physiotherapy in the intensive care unit and on the ward: breathing exercises and respiratory muscles

119. Asthma: issues in rehabilitation and physical therapy

120. The eclectic world of respiratory nursing

151. Mechanisms of allergic inflammation of the airways

152. Dilemmas and progress in understanding childhood asthma

153. Flexible bronchoscopy in the diagnosis of paediatric lung diseases

154. Physiology and cardiometabolic comorbidities in obstructive sleep apnoea

155. Advances in long-term noninvasive positive pressure ventilation

156. Functional lung and pulmonary arterial imaging

157. Epithelial cells: role in health and disease

158. Exercise training: new populations, new techniques

159. Biomarkers and outcomes of community-acquired pneumonia

160. Progress in pathology of lung cancer

161. Paediatric epidemiology: predicting outcomes of wheeze, antenatal growth, early life exposures and outcome of premature birth

162. Clinical characteristics of patients with pulmonary hypertension

163. Exercise assessment in different diseases

164. Smoking-related disorders and smoking prevention

213. Understanding the burden of chronic respiratory diseases: what decision makers need to know

214. Mechanisms of acute lung injury and mesenchymal cell treatment

215. Clinical application of exhaled biomarkers

216. Molecular pathology and functional genomics of lung disease

217. Cardio-pulmonary interactions

218. Viral respiratory infections in children: causes and consequences

219. Indoor hazards and respiratory disease: irritants and allergens

220. Genes, environment and obstruction

221. Obstructive sleep apnoea: the heart and the brain

222. Comorbidities and impact on society of asthma and COPD

223. Models of disease and drug actions

224. Smoking-related diseases and smoking cessation

225. Tuberculosis: from bench to bedside

226. T-cell subsets

234. Phenotyping asthma: a clue for treatments?

235. Imaging in COPD

236. The best abstracts in rehabilitation and chronic care 2011 (sponsored by Nutricia Advanced Medical Nutrition)

237. What is new in tuberculosis immunodiagnosis?

238. The burden of work-related respiratory disease: known and new end-points

239. Surgery for lung cancer: pre-operative evaluation and results

240. Resuscitation and ventilation in the baby and infant

241. Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis

242. Tuberculosis in immunocompromised hosts

243. Lung cancer: molecular pathology and functional genomics

244. Progress in endoscopy for the diagnosis of lung cancer

245. Mechanical ventilation and lung injury: new advances

246. Genetic and molecular background in pulmonary fibrosis

247. Advances in lung function testing from infancy to adulthood

248. Acute respiratory failure

249. Intensive care outcome

250. Noninvasive ventilation in the acute setting: education, organisation, H1N1, paediatrics, weaning, diagnostic procedures and special considerations

251. New evidence in home mechanical ventilation

252. Respiratory and skeletal muscle assessment in health and disease

253. Lung and airway function

254. Clinical physiology for clinical problems

255. Innovative methods in exercise testing

256. Epidemiology, diagnosis and treatment in obstructive sleep apnoea

257. Physiology and diagnostic technology in obstructive sleep apnoea

258. Cardiometabolic and neurocognitive changes in obstructive sleep apnoea

259. Comorbid obstructive sleep apnoea (OSA) and OSA comorbidities

260. Obstructive sleep apnoea: clinical aspects I

261. Treatment of human pulmonary hypertension

262. Physiology of human pulmonary hypertension

263. Clinical features of pulmonary hypertension

264. Clinical features of pulmonary thromboembolism

265. Pulmonary hypertension in hypoxic lung disease

266. Treatment of pulmonary hypertension

267. Chest wall trauma and airway management

268. General thoracic surgery I

269. Lung transplantation

270. Aetiology, diagnosis and outcomes in community-acquired pneumonia

271. Assessment of severity and predictors of outcomes in community-acquired pneumonia

272. New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections

273. Infection in the immunocompromised host: infrequent aetiologies

274. Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis

275. Antimicrobial treatment and resistance in lower respiratory tract infections

276. Clinical tuberculosis

277. Management of tuberculosis

278. Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis

279. Tuberculosis epidemiology and public health

280. Risk assessment for tuberculosis

281. Extrapulmonary tuberculosis and surgical interventions

282. Pulmonary and extrapulmonary tuberculosis

283. Clinical challenges in tuberculosis

284. Epidemiology of lung cancer and screening

285. Imaging, functional evaluation and staging for lung cancer patients

286. Palliation and morbidity in lung cancer patients

287. Biomarkers and other new methods for lung cancer

288. Instructive clinical aspects of lung cancer

289. Pleural and mediastinal malignancies: management and rare clinical cases

290. Medical education

320. COPD: mechanisms and biomarker

321. Barrier functions in sepsis and acute lung injury

322. Treatment options and tumour biology of malignant pleural mesothelioma

323. COPD: burden of disease, imaging and management

324. Comorbidities and management in primary care

325. Noninvasive ventilation on the intensive care unit: from novel application to end of life issues

326. Chest physiotherapy and breathing retraining

327. Novel clinical features of acute and chronic lung diseases

328. Measuring physical activity and exercise performance in chronic lung disease: implications for rehabilitation

329. Role of infection in exacerbations of COPD

330. Quality control in lung function and exercise-related issues

331. Obstructive sleep apnoea: inflammation and metabolism

332. Improving outcomes after lung transplantation

333. Epithelial cell biology

357. Pulmonary infections and sepsis

358. E-learning

359. Important new developments in paediatric respiratory physiology

360. New insights in the incidence, variation and risk factors of asthma

361. Growth factors and fibrogenesis: are they good, bad or both?

362. Obstructive sleep apnoea in children and adults

363. Sleep and weight: heavy under pressure

364. Physical activity monitors: from toy to valid tool?

365. Asthma: basic science and clinical studies

366. Inflammation and genes in childhood asthma

367. Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis

368. Environmental exposure and disease mechanisms

369. Experimental pulmonary hypertension

370. Biomarkers and exacerbations of asthma and COPD

378. Non-tuberculous mycobacteria pulmonary infections

379. Early wheezing conditions in childhood

380. Late-Breaking Abstracts Session: New mechanisms in airway disease

381. Highlights in lung function 2011

382. New treatments for airway disease

383. Pathobiology of experimental pulmonary hypertension

384. Outdoor air pollution studies

385. Understanding disease and drug mechanisms

386. Obstructive sleep apnoea as a comorbidity

387. Challenges in chronic disease management: helping individuals with chronic lung disease remain stable

388. Insight into mechanisms of respiratory infections

389. Phenotyping and monitoring of airway diseases

390. Treatment beyond inhalers: endoscopic lung volume reduction

391. Molecular markers: diagnosis and management of malignant pleural effusions

393. COPD diagnosis

394. COPD mechanisms

395. New insights in management of interstitial and vascular lung diseases

396. What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life

397. Challenges in rehabilitation: some old dilemmas revisited with some solutions?

398. Imaging in oncology and infectious diseases

399. The basic and the future: pure diagnostic or dedicated wavelengths play

400. A little bit of everything: interventional pneumology

401. Different profiles of sarcoidosis and other granulomatous disorders

402. Clinical perspectives in several interstitial diseases

403. Quality of diagnosis and assessment in primary care

404. Recent advances in noninvasive ventilation used for treating acute respiratory failure

405. Lung development and neoplasia

406. COPD: clinical studies and animal cell models

407. Immunology and cell biology of asthma and COPD

408. Phagocytes and dendritic cells

409. Cell biology of lung disease

410. Novel mechanisms in lung injury

411. Obstructive sleep apnoea: clinical aspects II

412. Prediction of pulmonary thromboembolism

413. Asthma management and response

414. Drug delivery and pharmacokinetics II

415. Airways disease comorbidities and general aspects

416. Update on monitoring airway diseases

417. Bronchial hyperresponsiveness and exhaled and sputum biomarkers

418. Treatment strategies, systemic manifestations and biomarkers in airway diseases

419. Diagnosis and treatment of inflammatory respiratory diseases

420. Experimental modulation of airway inflammation

421. Respiratory epidemiology: quality of life, therapy and socioeconomics

422. Respiratory epidemiology: prevalence, incidence and remission

423. Respiratory epidemiology: methods, definitions and phenotypes

424. Work-related respiratory diseases and specific exposures

425. Work, the environment and respiratory disease

426. Anti-smoking interventions: prevention and treatment

427. Epidemiology of smoking and smoking cessation interventions

428. Coping and lifestyle in childhood asthma

429. Biological correlates and comorbidities of childhood asthma/allergy

430. Cystic fibrosis: clinical and laboratory studies

431. Issues in paediatric and neonatal intensive care

432. General thoracic surgery II

433. Influenza A (H1N1): lessons after the epidemic

434. Challenges in tuberculosis control

435. Novel strategies for the diagnosis of tuberculosis

436. Treatment of tuberculosis and adverse drug reactions

437. Quality management for lung cancer patients

460. Late-Breaking Abstracts Session: New treatments and targets for airway disease

461. Innovative diagnostic methods for lung cancer

462. Appropriate use of antibiotics in respiratory infections in Europe (the GRACE project)

463. Biomarkers in sarcoidosis

464. Access to the periphery: solitary periphery nodule

466. COPD mechanisms

467. Cystic fibrosis: new basic, clinical and bacteriological knowledge

468. Rare lung diseases in children

469. Lung cell injury and repair

470. Morphological and functional imaging in obstructive airway disease

471. Disease management in specific primary care populations

479. Cystic fibrosis: detection and monitoring of early lung disease

482. How to improve lung cancer care

483. The impact of the organisation of care on costs: the role of the physician in home care

484. Translational models of airway disease

485. Smoking-related disorders

486. Surgical options in pulmonary infections

487. Severity, comorbidities and outcomes in community-acquired pneumonia

488. Phenotyping airway diseases

489. Continuous medical education

490. Physiological basis of respiratory disease

491. Molecular: pathology of infectious and inflammatory lung disease

492. Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease

493. Role of the biomarkers in airway diseases

494. Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD

495. Treating childhood asthma

502. Clinical approach of diffuse parenchymal lung disease

503. COPD: integrated care and rehabilitation

504. Innovative methods in clinical physiology

506. Asthma mechanisms

507. Tuberculosis in special populations

508. Novel mechanisms in COPD

509. Clinical features of human pulmonary hypertension

510. Asthma: improving diagnosis and management for reaching better control

511. The work environment in the clinic

512. Obstructive sleep apnoea: physiology, diagnostic tools and technology

513. Tuberculosis in pregnancy and childhood

514. Integrated care and telehealth in primary care

515. Mechanical ventilation and weaning